Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on Novartis AG, with a price target of CHF130.00.

Sachin Jain has given his Buy rating due to a combination of factors, notably management’s confidence that Novartis can sustain around 5–6% annual sales growth through 2030 despite looming loss-of-exclusivity risks. He highlights that the expected 2030 revenue base is projected to exceed market consensus, supported by early momentum from newer products such as Rhapsido in chronic spontaneous urticaria and the planned rollout of ianalumab in a high unmet-need autoimmune setting.

In addition, Jain emphasizes that the anticipated patent expirations for major drugs like Cosentyx, Kesimpta and Kisqali are staggered across regions, reducing the risk of a sharp revenue drop and allowing time for new launches to fill the gap. He underlines the depth of the late-stage pipeline, including remibrutinib in multiple sclerosis, pelacarsen in cardiovascular disease, abelacimab and Avidity’s RNA-based programs, which collectively offer substantial multi‑billion-dollar peak sales potential and underpin confidence that pipeline growth can more than offset the patent headwinds.

In another report released on February 6, TipRanks – Google also reiterated a Buy rating on the stock with a CHF137.00 price target.